Takeda Pharmaceutical and Noile-Immune Biotech, a Tokyo-headquartered biotechnology company, have agreed to develop a chimeric antigen receptor T cell therapy (CAR-T).

The CAR-T cell therapy was developed by Professor Koji Tamada at Yamaguchi University in Japan, and Noile-Immune has exclusive license for this platform technology. The CAR-T therapy produces cytokines, chemokines, and other molecules that are planned to potentially influence or alter the tumor microenvironment of solid tumor tissues to enhance the anti-tumor effect of the therapy.

In addition to providing resources required for implementation, Takeda will make a technology-access payment to Noile-Immune Biotech and an equity investment. Takeda will have exclusive options to obtain licensing rights for the development and commercialization of Noile-Immune’s pipeline and products resulting from this partnership on pre-agreed terms. Additional terms of this agreement were not disclosed.

Takeda signed an agreement with Noile-Immune through its wholly owned subsidiary, Millennium Pharmaceuticals.

Source: Takeda Pharmaceutical Company